GR 144053

structure given in first source

Also Known As:

4-(4-(4-(aminoiminomethyl)phenyl)-1-piperazinyl)-piperidineacetic acid; 4-(4-(4-(aminoiminomethyl)phenyl)-1-piperazinyl)-piperidineacetic acid hydrochloride trihydrate; GR-144053; GR144053; GR144053F

Networked: 6 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - GR 144053: 6
  - Piperidines: 17
    - GR 144053: 6

Experts

1.	Davila, Antonio: 1 article (11/2020)
2.	Diamond, Scott L: 1 article (11/2020)
3.	Sims, Carrie A: 1 article (11/2020)
4.	Verni, Christopher C: 1 article (11/2020)
5.	Cooley, Brian C: 1 article (01/2007)
6.	Isogai, Noritaka: 1 article (01/2007)
7.	Kusada, Akiko: 1 article (01/2007)

Related Diseases

1.	Neointima 08/01/1998 - "These findings suggest that GR144053 inhibits platelet activation on the injured artery and improves vascular patency after thrombolysis with tPA, which furthermore results in suppression of neointima formation." 11/01/1997 - "6. According to the results of a time-dependent study in which GR144053 was given in combination with post injury treatment with losartan for 1, 3, 7 or 14 days, neointima formation could be reduced by treatment with GR144053 for just 7 days. " 11/01/1997 - "3. When the administration of GR144053 (1.0 mg kg-1 per hour) via an implanted osmotic pump was started 30 min before the injury and continued for the next 2 weeks, no suppression of neointima formation was observed, although platelet aggregation evoked ex vivo by adenosine diphosphate (ADP) at the end of treatment period was efficiently inhibited. " 11/01/1997 - "7. In conclusion, GR144053, a fibrinogen receptor antagonist, enhanced the inhibitory effect of losartan, an AT1 receptor antagonist, on neointima formation in the damaged carotid artery of hamsters." 11/01/1997 - "GR144053, a fibrinogen receptor antagonist, enhances the suppression of neointima formation by losartan, an angiotensin II receptor antagonist, in the injured carotid artery of hamster."
2.	Vascular System Injuries 11/01/1997 - "1. The present study investigated the inhibitory effect of losartan, a type 1 angiotensin II (AT1) antagonist, and of combined treatment with losartan and GR144053, a fibrinogen receptor (GPIIb/IIIa) antagonist, on neointima formation subsequent to vascular injury in the hamster carotid artery. "
3.	Activated Protein C Resistance (APC Resistance) 06/01/1999 - "In this study, we have measured platelet-dependent APC resistance and the effect of aspirin and a platelet glycoprotein IIbIIIa antagonist (GR144053F) on this phenomenon. " 06/01/1999 - "In vitro inhibition of platelet activation with aspirin had no effect, but the fibrinogen receptor antagonist, GR144053F, inhibited platelet-dependent APC resistance. "
4.	Pathologic Constriction (Stenosis) 07/01/1999 - "Comparison of the antithrombotic effects and bleeding risk of fractionated aurin tricarboxylic acid and the GPIIb/IIIa antagonist GR144053 in a hamster model of stenosis." 07/01/1999 - "The present study compared the antithrombotic properties of fractionated aurin tricarboxylic acid (ATA), an inhibitor of platelet glycoprotein (GP) Ib, and GR144053, a GPIIb/IIIa antagonist, in a hamster model of stenosis. "
5.	Thrombosis (Thrombus) 07/01/1999 - "In conclusion, both inhibition of platelet activation by ATA or GR144053 prevent arterial thrombosis and enhance the thrombolytic effect of tPA, but GR144053 was more protective in its antithrombotic effect and more effective during thrombolytic therapy than ATA." 01/01/2007 - "In a further evaluation of the model, three pharmacologically treated groups of mice were evaluated, with drug infusion immediately before thrombus induction: (1) saline (control), (2) heparin (60 units/kg), and (3) GR144053, a GPIIb/IIIa-specific antagonist (10 mg/kg). " 08/01/1998 - "Effect of GR144053, a fibrinogen-receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tPA in the injured carotid artery of the hamster."

Related Drugs and Biologics

1.	Platelet Membrane Glycoproteins
2.	Fibrinogen Receptors
3.	Losartan (Cozaar)
4.	Aurintricarboxylic Acid
5.	Aspirin (Acetylsalicylic Acid)
6.	Angiotensin II
7.	Angiotensin Receptor Antagonists
8.	Heparin (Liquaemin)
9.	Adenosine Diphosphate (ADP)
10.	fibrin fragment D (D-dimer)

Related Therapies and Procedures

1.	Thrombolytic Therapy